Teva Pharmaceutical Industries (NYSE:TEVA) has been back in the spotlight after CEO Richard D. Francis discussed the company’s Pivot to Growth plan at the Leerink Global Healthcare Conference in Miami.

The recent pullback, with a 9.2% 30 day share price return and 6.7% 7 day share price return, comes after a strong run that leaves Teva on a 114.7% one year total shareholder return and a 252.4% three year total shareholder return. This suggests longer term momentum remains intact even as investors reassess the Pivot to Growth messaging and pipeline updates.

If this renewed focus on growth in healthcare is on your radar, it could be a good moment to look across the sector using our screener of 32 healthcare AI stocks as potential ideas to research next.

With Teva trading at US$31.50, an indicated 21.1% discount to the average analyst price target and a reported intrinsic discount of 46.6%, the key question is whether this signals genuine value or if the market is already accounting for future growth.

Most Popular Narrative: 17.2% Undervalued

Teva Pharmaceutical Industries’ most followed narrative points to a fair value of $38.05 versus the last close at $31.50, putting that valuation gap in the spotlight for anyone tracking the Pivot to Growth story.

The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher margin revenue streams and offset headwinds from traditional generics, powering long term EBITDA growth.

Want to see what sits behind that earnings and cash flow story? The narrative leans on measured revenue growth, rising margins, and a future profit multiple that assumes real confidence in the 2030 earnings profile. Curious which specific assumptions have to land for that $38.05 fair value to hold up?

Result: Fair Value of $38.05 (UNDERVALUED)

However, this hinges on a concentrated set of branded drugs and a sizeable net debt position above US$15b. Both of these factors could quickly challenge that valuation story.

Another Angle On Valuation

Here is the tension. On one hand, our model points to Teva trading 46.6% below its estimated future cash flow value, which screens as undervalued. On the other, the current P/E of 26x sits above the US pharmaceuticals average of 18.8x, the peer average of 20.5x, and even its own 23.9x fair ratio. Is the discount real value or just higher valuation risk?

Next Steps

With mixed signals on valuation and growth, how does it all sit with you today, and are you comfortable with the trade off between opportunity and risk? Take a closer look at the underlying data, form your own view, and weigh up 4 key rewards and 2 important warning signs before you decide what comes next.

Looking for more investment ideas?

Before you move on, give yourself a stronger starting point by lining up a few more candidates that match the kind of opportunities you want to research next.

• Target potential mispricings by scanning our list of 46 high quality undervalued stocks that may be worth a closer look.
• Prioritise financial strength with the solid balance sheet and fundamentals stocks screener (41 results) so you are not ignoring companies that keep their foundations tight.
• Spot opportunities with staying power by checking out a 65 resilient stocks with low risk scores that could fit a more cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.